Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  leukemia
Stage/Subtype:  leukemia
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-11 of 11 for your search:
Start Over
Vaccine Therapy and Lenalidomide in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: H-30087, NCI-2013-01015, RV-CLL-PI-0715, TAIL, NCT01604031
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: BP-HM-001, NCI-2013-00518, NCT01744223
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 3 months to 21 years
Trial IDs: BP-004, NCI-2015-01890, NCT02065869
Recombinant Interferon Alpha-2a and Sargramostim or Vaccine Therapy in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J05121, NCI-2011-00392, CDR0000492005, JHOC-J05121, NA_00001887, NCT00363649
Vaccine Therapy with or without Pidilizumab in Treating Patients with Acute Myeloid Leukemia in Complete Remission after Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-412, NCI-2010-01612, NCT01096602
Vaccine Therapy after Donor Stem Cell Transplant in Treating Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-217, NCI-2013-00286, NCT01773395
Lenalidomide in Improving Hypogammaglobulinemia and Impaired Response to Vaccinations in Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0371, NCI-2014-01058, RV-CL-CLL-PI-002544, NCT01924169
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC138E, NCI-2014-02373, RV-CL-CLL-PI-003938, NCT02309515
Ibrutinib and Vaccine Therapies in Treating Patients with Asymptomatic, High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-15012, NCI-2015-00932, 2015C0098, NCT02518555
Vaccine Therapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 13H05, NCI-2013-01650, NCT01976520
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI-DSP7888-101, NCI-2015-01357, NCT02498665
Start Over